primary antibodies against ccna2  (Cell Signaling Technology Inc)

Journal: Evidence-based Complementary and Alternative Medicine : eCAM

Article Title: Anticancer Action of Xiaoxianxiong Tang in Non-Small Cell Lung Cancer by Pharmacological Analysis and Experimental Validation

doi: 10.1155/2021/9930082

Figure Lengend Snippet: Information on 20 core targets.

Article Snippet: Primary antibodies against FOSL2 (cat. #: 15832-1-AP), α -tubulin (cat. #: 11224-1-AP), and GAPDH (cat. #: 10494-1-AP) were from Proteintech, and CCNA2 (cat. #: 4656) was from Cell Signaling Technology.

Techniques:

Journal: Evidence-based Complementary and Alternative Medicine : eCAM

Article Title: Anticancer Action of Xiaoxianxiong Tang in Non-Small Cell Lung Cancer by Pharmacological Analysis and Experimental Validation

doi: 10.1155/2021/9930082

Figure Lengend Snippet: The cytotoxic effects of XXXT on lung cancer cells, RT-qPCR array, and western blot for core targets. (a) The inhibition rates of H460 and A549 cells treated with XXXT (0–1000 μ g/mL) for 72 h were determined using CCK8 assay. A549 or H460 treated with XXXT at IC 50 for 72 h were harvested for analysis (b–e). (b) Heatmap of 20 core targets mRNA expression in the control group and XXXT treatment group. The significant difference of core targets in A549 and H460 cells (c) was observed, including expression of CCNA2 and FOSL2 mRNA. The protein levels of CCNA2 and FOSL2 were determined by western blot (d). Statistical analysis of CCNA2 and FOSL2 proteins expression intensity (e). The above data are presented as mean ± SD for three independent experiments. NS, not significant, ∗ P < 0.05 and ∗∗ P < 0.01 showed significant difference vs. the control group.

Article Snippet: Primary antibodies against FOSL2 (cat. #: 15832-1-AP), α -tubulin (cat. #: 11224-1-AP), and GAPDH (cat. #: 10494-1-AP) were from Proteintech, and CCNA2 (cat. #: 4656) was from Cell Signaling Technology.

Techniques: Quantitative RT-PCR, Western Blot, Inhibition, CCK-8 Assay, Expressing, Control